- RecruitingPHASE1, PHASE2
Study to Assess Safety, Efficacy, and Cellular Kinetics of YTB323 in Generalized Myasthenia Gravis
This study is looking at a new cell therapy called YTB323 for people with a severe type of myasthenia gravis, a muscle weakening condition. It aims to see if it's safe and effective for patients who haven't responded well to other treatments.
For: Generalized Myasthenia GravisUnited States · France · Japan - Active not recruitingPHASE1, PHASE2
An Open-label, Study to Assess Safety, Efficacy and Cellular Kinetics of YTB323 in Severe, Refractory Systemic Lupus Erythematosus
This study is testing a new treatment called YTB323 for severe lupus that hasn't responded to other medicines. Researchers want to see if it's safe, how well it works, and how it affects the body's cells in people aged 18-65.
For: Systemic Lupus Erythematosus · Lupus NephritisAustralia · France · Germany